Effects of Canakinumab and Betamethasone on Glucose Metabolism and Pro-Inflammatory Cytokine Levels in Patients with Gout

Trial Profile

Effects of Canakinumab and Betamethasone on Glucose Metabolism and Pro-Inflammatory Cytokine Levels in Patients with Gout

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2015

At a glance

  • Drugs Canakinumab (Primary) ; Betamethasone
  • Indications Gout; Gouty arthritis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 22 Jul 2015 New trial record
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top